Chronic daily administration of oral etoposide in refractory lymphoma

John D. Hainsworth, David H. Johnson, Sheryl R. Frazier, F. Anthony Greco

Research output: Contribution to journalArticlepeer-review

81 Scopus citations


In a phase II study, 25 patients with previously treated lymphoma received oral etoposide for 21 consecutive days. All patients were considered incurable with standard therapy. Etoposide was administered at 50 mg/m2 per day: courses were repeated every 28-35 days, depending on myelosuppression. 15 patients (60%) had partial responses (95% CI 41-77%), while 10 patients had no response. Median time to disease progression was 5 months (range 2-13 months). Oral etoposide was active against indolent and aggressive (intermediate and high grade) lymphomas; however, median time to progression was only 3 months in aggressive lymphoma compared with 8 months in indolent lymphoma. Myelosuppression was the major side-effect; 7 patients (28%) had a leucocyte nadir below 1000/μl during the first course, and 11 patients required dose reduction during subsequent courses due to unacceptable leukopenia. All patients had total alopecia, but other side-effects were uncommon. These results highlight the importance of schedule in the administration of etoposide.

Original languageEnglish (US)
Pages (from-to)818-821
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Issue number7
StatePublished - 1990

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Chronic daily administration of oral etoposide in refractory lymphoma'. Together they form a unique fingerprint.

Cite this